DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT05785754. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, open-label, Phase 1 study to assess the effects of DCSZ11 as a monotherapy and in combination in patients with advanced or metastatic solid tumors. The study consists of an Escalation Phase (Phase 1a) and a Dose Expansion/Optimization Phase (Phase 1b).
Study identification
- NCT ID
- NCT05785754
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 320 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 27, 2023
- Primary completion
- Nov 30, 2026
- Completion
- Nov 30, 2026
- Last update posted
- Jun 25, 2025
2023 – 2026
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama | Birmingham | Alabama | 35294 | Recruiting |
| Mayo Clinic | Phoenix | Arizona | 85054 | Recruiting |
| HonorHealth | Scottsdale | Arizona | 85258 | Recruiting |
| University of Colorado | Aurora | Colorado | 80045 | Recruiting |
| Sarah Cannon Research Institute Denver Healthone | Denver | Colorado | 80218 | Recruiting |
| Yale Cancer Center | New Haven | Connecticut | 06519 | Recruiting |
| Mayo Clinic | Jacksonville | Florida | 32224 | Recruiting |
| University of Miami | Miami | Florida | 33136 | Recruiting |
| John Hopkins Sidney Kimmel Comprehensive Cancer Center | Baltimore | Maryland | 21231 | Recruiting |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | Completed |
| Mayo Clinic | Rochester | Minnesota | 55905 | Recruiting |
| MonteFiore | The Bronx | New York | 10461 | Recruiting |
| Ohio State University | Columbus | Ohio | 43210 | Recruiting |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 21 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05785754, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 25, 2025 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05785754 live on ClinicalTrials.gov.